Treatment
of multiple sclerosis with anti-measles cow colostrum
Ebina T, Sato
A, Umezu K, Aso H, Ishida N, Seki H, Tsukamoto T, Takase S, Hoshi
S, Ohta M.
Previous virological
and immunological studies have suggested that multiple sclerosis (MS)
is an auto-immune disease triggered by a virus infection. In order
to inhibit the growth of measles virus in the patient's jejunum, we
obtained an IgA-rich cow colostrum containing anti-measles lactoglobulin
resistant to proteases. This colostrum was orally administered to
patients with MS to investigate its effect on the course of the disease.
Measles-positive antibody colostrum was orally administered every
morning to 15 patients with MS at a daily dosage of 100 ml for 30
days. Similarly, measles-negative antibody (less than 8) control colostrum
was orally administered to 5 patients. As a clinical assessment, disability
scores developed by the International Federation of Multiple Sclerosis
Societies were used. As a result, of 7 high NT titre (512-5120) anti-measles
colostrum recipients 5 patients improved and 2 remained unchanged.
Among 8 low NT titre (8-32) anti-measles colostrum recipients 5 patients
improved and 3 remained unchanged. However, of 5 negative NT titre
(less than 8) colostrum recipients 2 patients remained unchanged and
3 worsened. No side-effects were observed in colostrum recipients.
These findings suggest the efficacy of orally administered anti-measles
colostrum in improving the condition of MS patients (P less than 0.05).
Articles
71
